Eli Lilly & Co. Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers Eli Lilly and Company's (LLY) Form 10-Q for the quarterly period ended June 30, 2025. The company operates as a single segment focused on the discovery, development, manufacturing, and marketing of pharmaceutical products globally. As of August 4, 2025, there were approximately 946.5 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $15,557.7 million | $11,302.8 million | $28,286.2 million | $20,070.8 million |
| Net Income | $5,660.5 million | $2,967.0 million | $8,419.8 million | $5,209.9 million |
| Diluted EPS | $6.29 | $3.28 | $9.35 | $5.76 |
| Gross Margin % | 84.3% | 80.8% | 83.5% | 80.8% |
| Operating Cash Flow (YTD) | $4,752.5 million | $2,632.2 million | $4,752.5 million | $2,632.2 million |
| Total Debt | $39.90 billion | $33.64 billion (Dec 2024) | $39.90 billion | $33.64 billion (Dec 2024) |
| Cash & Equivalents | $3,375.9 million | $3,268.4 million (Dec 2024) | $3,375.9 million | $3,268.4 million (Dec 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 38% in Q2 and 41% YTD compared to 2024. Growth was driven primarily by volume increases in Mounjaro (tirzepatide) and Zepbound (tirzepatide), partially offset by lower realized prices.
- Profitability: Net income surged 91% in Q2 and 62% YTD. Gross margin expanded to 84.3% in Q2 due to improved production costs and favorable product mix.
- Expenses:
- R&D: Increased 23% in Q2 and 16% YTD due to continued investment in the pipeline.
- Acquired IPR&D: Significant one-time charge of $1.73 billion YTD 2025 (vs. $264.8 million in 2024), primarily related to the acquisition of Scorpion Therapeutics' PI3Kα inhibitor program.
- Special Charges: Q2 2024 included a $435 million litigation charge; Q2 2025 had no such charges.
- Debt: Total debt increased by $6.26 billion to $39.90 billion, driven by a $6.50 billion fixed-rate note issuance in February 2025 to fund acquisitions and general business purposes.
Guidance, Outlook, and Risks
- Product Pipeline:
- Tirzepatide: FDA application submitted for pediatric type 2 diabetes; Phase 3 cardiovascular outcomes trial met primary endpoint.
- Orforglipron: Phase 3 trials for obesity and type 2 diabetes met primary endpoints.
- Donanemab: EMA issued a positive opinion for early symptomatic Alzheimer's disease.
- Supply Chain: Tirzepatide supply currently exceeds demand in the U.S., though periodic unavailability may occur in specific markets due to complex supply chain dynamics. The company is actively addressing counterfeit and compounded incretin products.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 is expected to increase the effective tax rate to approximately 19% for 2025 while decreasing tax payments in the second half of the year.
- Regulatory & Pricing Risks:
- Continued pressure on drug pricing, including potential "most-favored-nation" pricing mandates and Medicare price negotiations under the Inflation Reduction Act (Jardiance selected for 2026 pricing).
- Significant litigation exposure regarding insulin pricing, 340B program disputes, and product liability claims for incretin medicines (Mounjaro, Zepbound, Trulicity).
- Acquisitions: In July 2025, the company acquired Verve Therapeutics (up to $1.3 billion potential consideration) and SiteOne Therapeutics (up to $1.0 billion potential consideration).
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of volume growth for Mounjaro and Zepbound against the backdrop of lower realized prices and potential pricing pressures.
- Acquisition Impact: Assess the integration and future cash flow potential of recent acquisitions (Scorpion, Verve, SiteOne) and the impact of the $1.73 billion IPR&D charge on future earnings.
- Supply Chain Capacity: Monitor manufacturing capacity expansion plans to ensure supply meets global demand for tirzepatide and other high-growth products.
- Legal Exposure: Review the status of insulin pricing litigation, 340B program challenges, and product liability suits regarding incretin medicines for potential financial impact.
- Tax Rate Volatility: Confirm the final impact of the OBBBA on the full-year 2025 effective tax rate and cash tax payments.